# Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

> **NCT04101331** · PHASE2 · COMPLETED · sponsor: **Affimed GmbH** · enrollment: 108 (actual)

## Conditions studied

- Peripheral T Cell Lymphoma
- Transformed Mycosis Fungoides

## Interventions

- **DRUG:** AFM13

## Key facts

- **NCT ID:** NCT04101331
- **Lead sponsor:** Affimed GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-13
- **Primary completion:** 2022-05-11
- **Final completion:** 2024-01-11
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04101331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04101331, "Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04101331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*